re: marsbar Hey numbskull.
Recurring revenue some way off yes, but don't discount milestone payments due from Medtronic. I have a suspicion that cleverly when negotiations started over a year ago, XBL and Med merged the two technical teams so that if/when negotiations were completed they were already off to a running start on collaboration. So development is already basically a year ahead, and at each stage of development progress, XBL will get lumps of cash.
Not sure of background of ACU, but I like the look of it at the moment...
- Forums
- ASX - By Stock
- is it time for biotechs?
XBL
xceed biotechnology ltd
re: marsbar Hey numbskull.Recurring revenue some way off yes,...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online